Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBT-708 monotherapy in advanced solid tumors
NCT06993870Phase 1Recruiting
- Sponsor
- 3SBio
- Start
- Jun 2025
- Primary completion
- Mar 2026
- Modality
- Biological product
- Countries
- 1
01
Overview
Phase 1, open-label trial of HBT-708 in solid tumor (advanced stage) (7 arms), sponsored by 3SBio. Primary endpoints: Number of participants with any treatment-emergent adverse event (TEAE) and dose-limiting toxicities up to 24 months and Determine the maximum tolerated dose (MTD) and the maximum administration dose up to 24 months. Started Jun 2025; status: recruiting.
02
Drugs
HBT-708
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06993870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06993870.